Lessons From a Citywide Narcan Rollout: WRAP® Adds Former NYPD Deputy Commissioner Edward Delatorre Jr. to Its Board

Wrap Technologies appointed former NYPD Deputy Commissioner Edward Delatorre Jr. to its board, effective October 20, 2026. The company highlighted his role in expanding the NYPD’s Narcan program as a parallel to its effort to make non-lethal response technology, training and policy repeatable for public-safety agencies; the article gives no financial or adoption figures.

Analysis

This is a governance and commercialization signal, not evidence of incremental demand. The potentially valuable asset is Delatorre’s experience translating a pilot into repeatable agency procedures: for WRAP, procurement may depend as much on training, policy approval, and ongoing implementation as on device performance. If that expertise helps shorten those steps, it could improve adoption quality and lower the risk that deployments remain isolated trials. But the Narcan analogy is not proof of product-market fit: agencies may assess non-lethal technologies under different use-of-force, liability, and public-scrutiny standards.

Near term (days), the appointment alone does not establish revenue or justify assuming a material valuation change. Over 1–3 months, look for verifiable evidence of agency conversions, repeat orders, deployment scale, and implementation timelines—not strategic language. Over 6–18 months, successful standardization could support a more durable adoption case; failure to convert pilots into sustained use would leave the appointment as a non-financial endorsement. Established public-safety vendors may remain advantaged where agencies prefer bundled systems, existing procurement relationships, and training infrastructure.

Contrarian read: the market may overvalue a prominent board addition while undervaluing the slow, policy-heavy work between endorsement and recurring deployments. The signal is modestly positive on execution capacity, but the commercial proof point is still missing.

Key Decisions for Investors

• Treat WRAP as a watch item, not a standalone buy catalyst; avoid extrapolating the Narcan rollout analogy into a forecast of product adoption.
• Over the next 1–3 months, monitor SEC filings and company updates for named agency deployments, pilot-to-purchase conversion, repeat orders, and evidence that Delatorre is materially involved in implementation.
• Reassess positively only if adoption evidence is accompanied by improving revenue or guidance; thesis weakens if pilots stall, deployments are not renewed, or use-of-force and liability concerns impede agency approvals.
• For an existing position, size exposure around demonstrated commercial traction rather than the board appointment; this release alone provides no defensible price target or clear relative-value trade.